Phase 2, Multicenter, Open-Label Study of CS-1008, A Hum

Project: Research project

Project Details

Description

Phase 2, Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal antibody targeting death receptor 5 (DR) in combination with gemcitabine in chemotherapy naive subjects with unresectable or metastatic pancreatic cancer
StatusFinished
Effective start/end date8/14/078/31/10

Funding

  • ICON CLINICAL RESEARCH, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.